ARCADIA, Fla., Nov. 06, 2018 (GLOBE NEWSWIRE) — PRESS RELEASE — Columbia Care LLC, a medical cannabis company, has announced that The British Standards Institution (BSI) has awarded a Good Manufacturing Practice (GMP) certificate to the Columbia Care Florida medical cannabis manufacturing facility, located in Arcadia, in accordance with the Florida Department of Health (DOH) requirements pertaining to the processing, extraction and production of medical cannabis.
The facility also reports tolerance specifications of less than one percent active pharmaceutical ingredient (API) variability across its initial production batches. While the Florida DOH Office of Medical Marijuana Use has not specified variability requirements, the Columbia Care manufacturing facility’s ability to achieve less than one percent API variability is well below the U.S. Food and Drug Administration’s 10 percent benchmark for API variability for pharmaceutical products sold in the U.S.
“Receiving GMP certification in Florida is a significant milestone for Columbia Care and demonstrates our unwavering national commitment to delivering the highest-quality cannabis-based medicines to our patients, not only throughout Florida but across the country,” said Nicholas Vita, chief executive officer of Columbia Care. “This GMP certification, coupled with less than one percent API variability, is a testament to our dedication to product quality, market leadership and hard-earned reputation for manufacturing the best medical cannabis products in the U.S. We are proud to continue raising the bar for the medical cannabis industry nationally and for patient and provider quality and consistency expectations by bringing superior production standards that surpass even the most stringent regulatory requirements. We are committed to working toward achieving less than one percent active ingredient variability for every production batch across all manufacturing facilities throughout the country.”